アラバマ州における転移性癌の臨床試験
アラバマ州内の拠点で、転移性癌に関する13件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clearview Cancer Institute, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07562152PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05868226Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- The University of Alabama at Birmingham, Birmingham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06943755A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- The Kirklin Clinic of UAB Hospital, Birmingham
- The University of Alabama at Birmingham, Birmingham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07335497A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第1相
36 Months – 22 Years · 全性別 · 2026/09/04更新 · NCT03911388A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Central Alabama Research, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/25更新 · NCT06216301SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。